Document Detail


Targeting the fibroblast growth factor receptors for the treatment of cancer.
MedLine Citation:
PMID:  23272905     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Receptor tyrosine kinases (RTKs) are transmembrane proteins that play a critical role in stimulating signal transduction cascades to influence cell proliferation, growth, and differentiation and they have also been shown to promote angiogenesis when they are up-regulated or mutated. For this reason, their dysfunction has been implicated in the development of human cancer. Over the past decade, much attention has been devoted to developing inhibitors and antibodies against several classes of RTKs, including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptors (EGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, interest in the fibroblast growth factor receptor (FGFR) class of RTKs as a drug target for the treatment of cancer has emerged. Signaling through FGFRs is critical for normal cellular function and their dysregulation has been linked to various malignancies such as breast and prostate cancer. This review will focus on the current state of both small molecules and antibodies as FGFR inhibitors to provide insight into their development and future potential as anti-cancer agents.
Authors:
Steven M Lemieux; M Kyle Hadden
Related Documents :
24377925 - Endosomal signaling and oncogenesis.
12505765 - Prestimulus modification of the startle reflex: relationship to personality and physiol...
10087005 - Both the antioxidant and d3 agonist actions of pramipexole mediate its neuroprotective ...
1824785 - Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic...
24396185 - Persistence of oxytocin receptors in the bovine uterus during the first 7 d after calvi...
19553485 - The influence of neuroactive steroid lipophilicity on gabaa receptor modulation: eviden...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Anti-cancer agents in medicinal chemistry     Volume:  13     ISSN:  1875-5992     ISO Abbreviation:  Anticancer Agents Med Chem     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-31     Completed Date:  2014-02-03     Revised Date:  2014-02-14    
Medline Journal Info:
Nlm Unique ID:  101265649     Medline TA:  Anticancer Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  748-61     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / administration & dosage*,  chemistry,  metabolism
Clinical Trials as Topic / methods
Drug Delivery Systems / methods*,  trends
Humans
Neoplasms / drug therapy*,  metabolism*
Receptors, Fibroblast Growth Factor / antagonists & inhibitors*,  metabolism
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Receptors, Fibroblast Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer.
Next Document:  Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment.